Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Newsletter "Clinica dell'Alcolismo"

N. 45 (2016)

La terapia farmacologia dell’alcolismo: il disulfiram e il naltrexone i primi due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte II

  • Felice Nava
  • Gisella Manzato
  • Sara Rosa
  • Fabio Caputo
Inviata
21 aprile 2017
Pubblicato
21-04-2017

Riferimenti bibliografici

  1. Ait-Daoud N., Johnson B.A. (2003), “Medication for the treatment of alcoholism”, in Johnson B.A., Ruiz P., Galanter M. (eds.), Handbook of clinical alcoholism treatment, Lippincott Williams & Wilkins, Baltimore, pp. 119-130.
  2. American Psychiatric Association (APA) (1987), Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, American Psychiatric Press, Washington DC.
  3. American Psychiatric Association (APA) (1996), Manuale Diagnostico e Statistico dei Disturbi Mentali, 4a Ed. (DSMIV, American Psychiatric Press, Washington DC, 1994), Masson, Milano.
  4. American Psychiatric Association (APA) (2001), Manuale Diagnostico e Statistico dei Disturbi Mentali, 4a Ed. TR. (DSM-IV-TR, American Psychiatric Press, Washington DC, 2000), Masson, Milano.
  5. Anton R.F., Mohak D.H., Lathan P. (1995), “The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior”, Alcoholism: Clinical and Experimental Research, 19: 92-99.
  6. Anton R.F., Mohak D.H., Lathan P. (1996), “The Obsessive Compulsive Drinking Scale: a new method of assessing outcomes in alcoholism treatment studies”, Archives of General Psychiatry, 53: 225-231.
  7. Anton R.F., O’Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A., for the COMBINE Study Research Group
  8. (2006), “Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: the COMBINE study: a randomized controlled trial”, JAMA, 295: 2003-2017.
  9. Anton R.F., Oroszi G., O’Malley S., Couper D., Swift R., Pettinati H., Goldman D. (2008), “An evaluation of muopioid receptor (OPRM1) as a predictor of naltrexone response in the tratment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study”, Archives of General Psychiatry, 65: 135-144.
  10. Arias A.J., Gelernter J., Gueorguieva R., Ralevski E., Petrakis I.L. (2014), “Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans”, American Journal on Addictions, 23: 288-293.
  11. Barth K.S., Malcolm R.J. (2010), “Disulfiram: an old therapeutic with new applications”, CNS and Neurological Disorders Drug Targets, 9: 5-12.
  12. Beck A.T., Ward C.H., Mendelson M. (1961), “An inventory for measuring depression”, Archives of General Psychiatry, 4: 561-571.
  13. Besson J., Aeby F., Kasas A., Lehert P., Potgieter A. (1998), “Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study”, Alcoholism: Clinical and Experimental Research, 22: 573-579.
  14. Bohn M.J., Krahn D.D. Staehler B.A. (1995), “Development and initial validation of a measure of drinking urges in abstinent alcoholics”, Alcoholism: Clinical and
  15. Experimental Research, 19: 600-606.
  16. Brewer C., Meyers R.J., Johnsen J. (2000), “Does disulfiram help to prevent relapse in alcohol abuse?”, CNS Drugs, 14: 329-341.
  17. Cloninger C.R. (1987), “Neurogenetic adaptive mechanisms in alcoholism”, Science, 236: 410-416.
  18. Cloninger C.R., Sigvardson S., Gilligan S.B., von Knorring A.L., Reich T., Bohman M. (1988), “Genetic heterogeneity and the classification of alcoholism”, Advances in Alcohol and Substance Abuse, 7: 3-16.
  19. Dimeff L.A. (1999), Brief alcohol screening and intervention for college students (BASICS): A harm reduction approach, The Guilford Press, New York.
  20. Erblich J., Earleywine M. (1995), “Distraction does not impair memory during intoxication: support for the attention-allocation model”, Journal of Studies on Alcohol, 56: 444-448.
  21. First M.B., Spitzer R.L., Gibbon M., Williams J.B. (1996) Structured Clinical Interview for DSM-IV Axis I Disorders (Patient Edition) (SCID-P), Biometrics Research Department, New York State Psychiatric Institute, New York.
  22. First M.B., Spitzer R.L., Gibbons M., Williams J.B.W. (1997), Structured Clinical Interview for DSM IV Axis I Disorders-Patient Edition, Biometrics Research Department, New York State Psychiatric Institute, New York.
  23. First M.B., Williams J.B.W., Spitzer R.L., Gibbon M. (2007), Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT), Biometrics Research Department, New York State Psychiatric Institute, New York.
  24. Fleming M.F., Barry K.L., McDonald R. (1991), “The Acohol Use Disorders Identification Test (AUDIT) in a college sample”, International Journal of Addictions, 26: 1173-1185.
  25. Franck J., Jayaram-Lindstrom N. (2013), “Pharmacotherapy for alcohol dependence: status of current treatments”, Current Opinion in Neurobiology, 23: 692-699.
  26. Fuller R.K., Gordis E. (2004), “Does disulfiram have a role in alcoholism treatment today?”, Addiction, 99: 21-24.
  27. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I. (1986), “Disulfiram treatment of alcoholism: a Veterans Adiministration Cooperation Study”, JAMA, 256: 1449-1455.
  28. Garbutt J.C. (2010), “Efficacy and tolerability of naltrexone in the management of alcohol dependance”, Current Pharmaceutical Design, 16: 2091-2097.
  29. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. (1999), “Pharmacological treatment of alcohol dependence: a review of the evidence”, JAMA, 281: 1318-1325.
  30. Garbutt J.C., Kranzler H.R., O’Malley S.S., Gastfriend D.R., Pettunati H.M., Silverman B.L., Loewy J.W., Ehrich E.W., for the Vivitrex Study Group (2005), “Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. A randomized controlled trial”, JAMA, 293: 1617-1625.
  31. Garbutt J.C., Grenblatt A.M., West S.L., Morgan L.C., Kampov-Polevoy A., Jordan H.S., Bobashev G.V. (2014), “Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of evidence”, Addiction, 109: 1274-1284.
  32. Greenfield S.F., Pettinati H.M., O’Malley S., Randall P.K., Randall C.L. (2010), “Gender differences in alcohol treatment: An analysis of outcome from the COMBINE study”, Alcoholism: Clinical and Experimental Research, 34: 1803-1812.
  33. Guy W. (1976), Clinical Global Impressions in ECDEU Assessment Manual for Psycopharmacology, Revised, Psycopharmacology Research Branch, National Institute of Health, Rockville, pp. 217-222.
  34. Haass-Koffler C.L., Leggio L., Kenna G.A. (2014), “Pharmacological approaches to reducing craving in patients with alcohol use disorders”, CNS Drugs, 28: 343-
  36. Hamilton M. (1960), “A rating scale for depression”, Journal of Neurology, Neurosurgery, and Psychiatry, 23: 56-62.
  37. Heinälä P., Alho H., Kiianmaa K., Lönnquist J., Kuoppasalmi K., Sinclair J.D. (2001), “Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebocontrolled
  38. trial”, Journal of Clinical Psychopharmacology, 21: 287-292.
  39. Helzer J.E., Robins L.N., Croughan J.L., Welner A. (1981), “Renard Diagnostic Interview: its reliability and procedural validity with physicians and lay interviewers”, Archives of General Psychiatry, 38: 393-398.
  40. Jacobson A.F., Goldstein B.J., Dominguez R.A., Steinbock R.M. (1986), “Interrater agreement and intraclass reliability measures of SAFTEE in psychopharmacologic clinical trials”, Psychopharmacology Bulletin, 22: 382-388.
  41. Johnson B.A., Ait-Daoud N., Roache J.D. (2005), “The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in alcoholism field”, Journal of Studies on Alcohol, suppl. 15: 157-167.
  42. Jonas D.E., Amick H.R., Feltner C., Wines R., Kim M.M., Shanahan E.,Rowe C.J., Garbutt J.C. (2014), “Genetic polymorphism and response to medications for alcohol use disorders: a systematic review and meta-analysis”, Pharmacogenomics, 15: 1687-1700.
  43. Kadden R.P., Carrol K., Donovan D., Cooney N., Monti P., Abrams D., Litt M., Hester R. (1992), “Cognitive-Behavioral Coping Skilss Therapy Manual: A Clinical
  44. Research Guide for Therapist Treating Individuals with Alcohol Abuse and Dependence”, in Mattson M.E. (ed.), Project MATCH Monograph Series, vol. 4, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rockville.
  45. Kahler C.W., Strong D.R., Read J.P. (2005), “Toward efficient and comprehensive measurement of the alcohol problems continuum in college students: the brief young adult alcohol consequences questionnaire”, Alcoholism: Clinical and Experimental Research, 29: 1180-1189.
  46. Kay S.R., Fiszbein A., Opler L.A. (1987), “The positive and Negative Syndrome Scale (PANSS) for schizophrenia”, Schizophrenia Bullettin, 13: 261-276.
  47. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P:, Holzback R., Kämpf P., Stracke R., Baehr R., Naber D., Wiedemann K. (2003), “Comparing and combining
  48. naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study”, Archives of General Psychiatry, 60: 92-99.
  49. Kiefer E., Jiménez-Arriero M.A., Klein O., Diehl A., Rubio G. (2008), “Cloninger’s typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone”, Addiction Biology, 13: 124-129.
  50. Koskenvuo M. (1997), The Finnish twin registry baseline characteristics, National Institute for Health and Welfare, University of Helsinki, Helsinki.
  51. Krampe H., Ehrenreich H. (2010), “Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment”, Current Pharmaceutical Design, 16: 2076-2090.
  52. Laaksonen E., Vuoristo-Myllys S., Koski-Jannes A., Alho H. (2013), “Combining medical tratment and CBT in treating alcohol-dependent patients: effects on life quality and general well-being”, Alcohol and Alcoholism, 48: 687-693.
  53. Levine J., Schooler N.R. (1986), “SAFTEE: a technique for the systematic assessment of side effects in clinical trials”, Psychopharmacology Bulletin, 22: 343-381.
  54. Longabaugh R., Wirtz P.W., Zywiak W.H., O’Malley S.S. (2010), “Network support as a prognostic indicator of drinking outcomes: the COMBINE Study”, Journal of Studies on Alcohol and Drugs, 71: 837-846.
  55. MacKillop J. (2006), “Factor structure of the alcohol urge questionnaire under neutral conditions and during a cueelicited urge state”, Alcoholism: Clinical and Experimental Research, 30: 1315-1321.
  56. Maremmani A.G.I., Pani P.P., Rovai L., Pacini M., Dell’Osso L., Maremmani I. (2011), “Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics”, International Journal of Environmental Research and Public Health, 8: 2816-2827.
  57. Martin C.S., Earleywine M., Musty R.E,, Perrine M.W., Swift R.M. (1993), “Development and validation of the biphasic alcohol effects scale”, Alcoholism: Clinical and Experimental Research, 17: 140-146.
  58. McLellan A.T., Luborsky L., Woody G.E., O’Brien C.P. (1980), “An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index”, Journal of Nervous and Mental Disease, 168: 26-83.
  59. Meyers R.J., Smith J.E. (1995), Clinical Guide to AlcoholTreatment: The Community Reinforcement Approach, Guilford Press, New York.
  60. Miller W.R. (1996), Form 90: A Structured Assessment Interview for Drinking and Related Behaviors (Test Manual), National Institute on Alcohol Abuse and
  61. Alcoholism (NIAAA), Bethesda.
  62. Miller W.R. (2004), Combined Behaviotral Intervention Manual, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda.
  63. Miller W.R., Zweben A., DiClemente C., Rychtarik R. (1994), “Motivational Enhancement TherapyManual: A Clinical Research Guide for Therapist Treating Individuals with Alcohol Abuse and Alcoholism”, in Mattson M.E. (ed.), Project MATCH Monograph Series, vol. 2, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rockville.
  64. Miller W.R., Tonigan J.S., Longabaugh R. (1995), “The Drinker Inventory Consequences (DrInC): An instrument for assessing adverse consequences of alcohol abuse”, in Mattson M., Marshall L.A. (eds.), Project MATCH Monograph Series, vol. 4, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rockville.
  65. Miller P.M., Book S.W., Stewart S.H. (2011), “Medical treatment of alcohol dependence: A systematic review”, International Journal of Psychiatry in Medicine, 42: 227-266.
  66. Mueser K.T., Noorsdy D.L., Fox L., Wolfe R. (2003), “Disulfiram treatment for alcoholism in severe mental illness”, American Journal on Addictions, 12: 242-252.
  67. Nava F., Manzato E. (2015), “Il trattamento farmacologico dell’alcolismo”, in Manzato E., Nava F. (a cura di), Il craving dell’alcolista: Neurobiologia, psicopatologia e pratica clinica. Trattamento alcologico, psichiatrico e dei
  68. disturbi d’ansia, vol. 2, FrancoAngeli, Milano, in press.
  69. Niciu M.J., Arias A.J. (2013), “Targeted opioid receptor antagonist in the treatment of alcohol use disorders”, CNS Drugs, 27: 777-787.
  70. Nowinski J., Baker S., Carroll K. (1995), “Twelve-Step Fsacilitation Therapy Manual: A Clinical Research Giuide for Therapist Treating Individuals with Alcohol Abuse and Dependence”, in Mattson M.E. (ed.), Project MATCH Monograph Series, vol. 1, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rockville.
  71. O’Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E. Rounsaville B. (1992), “Naltrexone and coping skills therapy for alcohol dependence: a controlled study”, Archives of General Psychiatry, 49: 881-887.
  72. O’Malley S.S., Garbutt J.C., Gastfriend D.R. (2007), “Efficacy of extendid-release naltrexone in alcohol dependent patients who are abstinent before tratment”, Journal of Psychopharmacology, 27: 507-512.
  73. O’Malley S.S., Corbin W.R., Leeman R.F. (2015), “Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety”, Journal of Clinical Psychiatry, 76: 207-213.
  74. O’Shea B. (2000), “Disulfiram revised”, British Journal of Hospital Medicine, 61: 264-272.
  75. Overall J.E., Gorham D.R. (1962), “The Brief Psychiatric Rating Scale”, Psychological Report, 10: 799-812.
  76. Petrakis I.L., Carroll K.M., Nich C., Gordon L.T., McCance-Katz E.F., Frankforter T., Rounsaville B.J., (2000), “Disulfiram treatment for cocaine dependence in
  77. methadone-maintained opioid addicts”, Addiction, 95: 219-228.
  78. Petrakis I.L., Poling J., Levinson C., Nich C., Carroll K., Rounsaville B.J. (2005), “Naltrexone and disulfiram in patients with alcohol dependence and comorbid
  79. psychiatric disorders”, Biological Psychiatry, 57: 1128-1137.
  80. Petrakis I.L., Poling J., Levinson C., Nich C., Carroll K., Ravelski E., Rounsaville B.J. (2006), “Naltrexone and disulfiram in patients with alcohol dependence and
  81. comorbid post-traumatic stress disorder”, Biological Psychiatry, 60: 777-783.
  82. Petrakis I.L., Ravelski E., Nich C., Levinson C., Carroll K., Poling J., Rounsaville B.J., VA VISN I MIRECC Study Group (2007), “Naltrexone and disulfiram in patients with alcohol dependence and current depression”, Journal of Clinical Psychopharmacology, 27: 160-165.
  83. Pettinati H.M., Weiss R.D., Miller W.R., Donovan D., Ernst D.B., Rounsaville B.J. (2004), Medical Management (MM) Treatment Manual, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda.
  84. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R., O’Brien C.P. (2008), “A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occcurring cocaine and alcohol dependence”, Addictive Behaviors, 33: 651-667.
  85. Ray L.A., Bujarski S., Chin P.F., Miotto K. (2012), “Pharmacogenetics of naltrexone in asiam americans: a randomized placebo-controlled laboratory study”, Neuropsychopharmacology, 37: 445-455.
  86. Reid L.D., Hunter G.A. (1984), “Morphine and naloxone modulate intake of ethanol”, Alcoholism, 38: 33-37.
  87. Reid L., Delconte J., Nichols M., Bilsky E., Hubbell C. (1991), “Tests of oipoid deficiency hypotheses of alcoholism”, Alcoholism, 8: 247-257.
  88. Rösner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. (2010), “Opioid antagonists for alcohol dependence”, Cochrane Database Systematic Reviews, 8: CD001867.
  89. Salokangas R.K., Poutanen O., Stengård E. (1995), “Screening for depression in primary care. Development and validation of the Depression Scale, a screening
  90. instrument for depression”, Acta Psychiatrica Scandinavica, 92: 10-16.
  91. Schuckit M.A. (1984), “Subjective responses to alcohol in sons of alcoholics and control subjects”, Archives of General Psychiatry, 41: 879-884.
  92. Selzer M.L. (1971), “The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument”, American Journal of Psychiatry, 127: 1653-1658.
  93. Sinclair J.D. (2001), “Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism”, Alcohol and Alcoholism, 36: 2-10.
  94. Skinner H.A., Allen B.A. (1982), “Alcohol dependence syndrome: measurement and validation”, Journal of Abnormal Psychology, 91: 199-209.
  95. Skinner H.A., Horn J.L. (1984) Alcohol Dependence Scale (ADS): User’s Guide, Addiction Research Foundation, Toronto.
  96. Skinner M.D., Lahmek P., Pham H., Aubin H-J. (2014), “Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis”, PloS One, 9: 1-15.
  97. Sobell L.C., Sobell M.B (1992), “Timeline follow-back: a technique for assessing self-reported alcohol consumption”, in Litten R.Z., Allen J.P. (eds.), Measuring
  98. Alcohol Consumption: Psychosocial and Biochemical Methods, Human Press, Totowa, pp. 41-72.
  99. Sobell M.B., Maisto S.A., Sobell L.C., Cooper A.M., Cooper T. Sanders B. (1980), “Developing a prototype for evaluating alcohol treatment effectiveness”, in Sobell L.C., Sobell M.B., Ward E. (eds.), Evaluating alcohol and drug abuse treatment effectiveness: Recent advances, Pergamon Press, New York, pp. 129-150.
  100. Sobell M.B., Sobell L.C., Klajner F., Pavan D., Basian E. (1986), “The reliability of a timeline method for assessing normal drinker college students’ recent drinking history: utility for alcohol research”, Addictive Behaviors, 11: 149-161.
  101. Soyka M., Rösner S. (2010), “Emerging drugs to treat alcoholism”, Expert Opinion on Emerging Drugs, 15: 695-711.
  102. Spanagel R., Kiefer F. (2008), “Drug for relapse prevention of alcoholism: ten years of progress”, Trends in Pharmacological Sciences, 29: 109-115.
  103. Specka M., Heilmann M., Lieb B., Scherbaum N. (2014), “Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment”, Clinical
  104. Neuropharmacology, 37: 161-165.
  105. Spitzer R.L., Williams J.B.W. (1985) Structured Clinical Interview for DSM-III-R, Patient Version, Biometric Research Department, New York State Psychiatric
  106. Institute, New York.
  107. Swift R.M., Oslin D.W., Alexander M., Forman R. (2015), “Adherence monitoring in naltrexone pharmacotherapy trials: A systematic review”, Journal of Studies on Alcohol and Drugs, 72: 1012-1018.
  108. Testino G., Leone S., Borro P. (2014), “Treatment of alcohol dependence: recent progress and reduction of consumption”, Minerva Medica, 105: 447-466.
  109. Tonigan J.S., Miller W.R., Brown J.M. (1997), “The reliability of Form 90: an instrument for assessing alcohol treatment outcome”, Journal of Studies on Alcohol, 58: 358-364.
  110. Tønnesen H., Egholm J.W., Oppedal K., Lauritzen J.B., Madsen B.L., Pedersen B. (2015), “Patient education for alcohol cessation intervention at the time of acute fracture surgery: study protocol for a randomised clinical multicentre
  111. trial on a gold standard programme (Scand-Ankle), BMC Surgery, 15: 1-9.
  112. Verheul R., Van Den Brink W., Geerlings P. (1999), “A threepathway psychological model of craving for alcohol”, Alcohol and Alcoholism, 34: 197-222.
  113. Volpicelli J.R., Davis M.A., Olgin J.E. (1986), “Naltrexone blocks the post-shock increase of ethanol consumption”, Life Sciences, 38: 841-847.
  114. Volpicelli J.R., O’Brien C.P., Alterman A.L., Hayshida M. (1990), “Naltrexone and the treatment of alcohol dependence: initial observations”, in Reid L.B. (ed.),
  115. Opioids, bulimia, alcohol abuse and alcoholism, Spinger-Verlag NY Inc., New York, pp. 195-214.
  116. Volpicelli J.R., Alterman A.I., Hayashida M., O’Brien C.P. (1992), “Naltrexone in the treatment of alcohol dependence”, Archives of General Psychiatry, 49: 876-
  118. Volpicelli J.R., Pettinati H.M., McLellan A.T., O’Brien C.P. (2001), Combining medication and psychosocial treatments for addictions: The BRENDA Approach, The Guilford Press, New York.
  119. World Health Organization (1996), Programme on Substance Abuse, Pharmacological Treatment of Substance Use Disorders: International Issues in Medications Development, WHO/PSA/96.10
  120. Worley M.J., Witkiewitz K., Brown S.A., Kivlahan D.R., Longabaugh R. (2015), “Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study”, Alcoholism: Clinical and Experimental Research, 39: 93-100.
  121. Zweben A., Pettinati H.M., Weiss R.D., Youngblood M., Cox C.E., Mattson M.E., Gorroochurn P., Ciraulo D. (2008), “Relationship between medication adherence and treatment outcomes: The COMBINE Study”, Alcoholism: Clinical and Experimental Research, 32: 1661-1669.

Metriche

Caricamento metriche ...